Table 3.
Twelve-month completion rates for olanzapine long-acting injectable or risperidone long-acting injectable (analysis 2)
| Study | Baseline medication(s) | OLAI n/N (%) | RLAI n/N (%) |
|---|---|---|---|
| HGKB24,25 (HGKA subgroup, data on file, Eli Lilly and Company and/or one of its subsidiaries) | OLAI | 522/642 (81.3) | |
| Lindenmayer et al31 (study B) | RLAI | 47/100 (47.0) | |
| Overall 12-month completion ratea | 522/642 (81.3) | 47/100 (47.0) |
Notes:
a
P < 0.001, olanzapine-LAI versus risperidone-LAI, per Pearson Chi-square test.
Abbreviations: HGKA, study F1D-MC-HGKA; HGKB, study F1D-MC-HGKB; n, number of patients completing 12 months of treatment; N, total number of patients treated; OLAI, olanzapine long-acting injectable; RLAI, risperidone long-acting injectable.